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Abstract
Background: Improvements in high-throughput technology and its increasing use have led to the
generation of many highly complex datasets that often address similar biological questions.
Combining information from these studies can increase the reliability and generalizability of results
and also yield new insights that guide future research.
Results: This paper describes a novel algorithm called BLANKET for symmetric analysis of two
experiments that assess informativeness of descriptors. The experiments are required to be
related only in that their descriptor sets intersect substantially and their definitions of case and
control are consistent. From resulting lists of n descriptors ranked by informativeness, BLANKET
determines shortlists of descriptors from each experiment, generally of different lengths p and q.
For any pair of shortlists, four numbers are evident: the number of descriptors appearing in both
shortlists, in exactly one shortlist, or in neither shortlist. From the associated contingency table,
BLANKET computes Right Fisher Exact Test (RFET) values used as scores over a plane of possible
pairs of shortlist lengths [1,2]. BLANKET then chooses a pair or pairs with RFET score less than a
threshold; the threshold depends upon n and shortlist length limits and represents a quality of
intersection achieved by less than 5% of random lists.
Conclusions:  Researchers seek within a universe of descriptors some minimal subset that
collectively and efficiently predicts experimental outcomes. Ideally, any smaller subset should be
insufficient for reliable prediction and any larger subset should have little additional accuracy. As a
method, BLANKET is easy to conceptualize and presents only moderate computational
complexity. Many existing databases could be mined using BLANKET to suggest optimal sets of
predictive descriptors.
Background
In contemporary high-throughput experiments, very
many descriptor values can be measured, leading to the
issue of correction for multiple testing to minimize false
positives at the cost of a high number of false negatives.
Reconciliation entails compromises that are to some
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extent arbitrary. A deterministic method is needed for
selecting a minimal, distinguished set of descriptors that
collectively provide effective, efficient prediction.
Researchers can subsequently investigate members of
such a subset to determine exactly how they are related
(e.g. are they genetically or chemically related?) and per-
haps why they should be inherently associated with pre-
dictions (e.g. are some members of the shortlists
components of a certain biochemical pathway?).
Meta-analysis is the general body of knowledge that
addresses integrating results from multiple experimental
programs on one topic; the purpose of this paper is to sug-
gest inclusion of BLANKET as an additional technique [3].
Regarding related papers, we note that Hess and Iyer
found that Fisher's combined p method applied to micro-
array data from spike-in experiments with RT-qPCR vali-
dation usually compared favorably to other methods [4].
However, they observed that other probe level testing
methods generally selected many of the same genes as dif-
ferentially expressed. So the method of finding differen-
tially expressed genes is not the critical issue. As they
further noted, current methods for analyzing microarray
data do better at ranking genes rather than maintaining
stated false positive rates.
Lists of descriptors ranked by informativeness are often
encountered in the general pursuit of relationships among
diseases, physiological processes, and the action of small
molecule therapeutics. Notable examples include the
Connectivity Map by Lamb et al. and the generation of
quantitative structure-activity relationships (QSAR) [5-7].
Kazius et al. considered N compounds, each of which
either is or is not toxic (e.g. mutagenic) [8]. They charac-
terized compounds by substructures, each compound
either including or not including a given substructure.
Inclusion of any substructure thereby can be considered as
a potential toxicity descriptor, and the point of Kazius et
al. was analysis of single experiments to determine toxic-
ity. BLANKET could be applied to the outcomes of two
experiments that use the same set of descriptors.
Regarding genes as descriptors (that is, expression of
mRNAs or proteins), a vast, public repository of data that
should support discovery of distinguished descriptor lists
is supported by the Gene Expression Omnibus (GEO)
project. GEO predominantly stores gene expression data
generated by microarray technology [9-11]. Another huge
data resource is Oncomine as developed by Rhodes et al.
[12,13]. Oncomine includes statistical reports on some
18,000 cancer gene expression microarrays.
Methods
Presented first are two synthetic examples. Suppose the
number of distilled descriptors n = 500 and the ranked list
for Experiment A is simply labeled 1, 2, ..., 500. Suppose
in the ranked list for Experiment B, the first ten are a ran-
dom permutation of 1, 2, ..., 10, and the other 490 are a
random permutation of 11, 12,...,500. We would expect
BLANKET to suggest an optimal subset of the first ten just
as is shown in Figure 1. (Should the very first descriptor
from one experiment be also the first of the other, then
BLANKET simply declares that descriptor to be the opti-
mal subset.) Note the appearance of the BLANKET surface:
a plateau of RFET values near 1 for very low p+q abruptly
falls to a floor of values near 0 as p+q increases. By defini-
tion of RFET, the extreme pairs with p = 0 or n, or q = 0 or
n values have RFET = 1, a property of all BLANKETs. So to
speak, the square BLANKET surface is supported at value
1 around its edge and dips to positive values ≤1 in its inte-
rior. Random BLANKETs (from randomly sorted lists)
seem to have no such patterns of plateaus and floors and
they generally have larger minimum values.
As a second synthetic example, suppose Experiment A
descriptors again have canonical ordering 1,2,...,500
while Experiment B has the same with local permutations
from weighted noise. Figure 2 shows that the noise in the
ranked lists can be sufficient to preclude shortlists of
length < 10, but three survive the < 20 criterion. Again
there is a plateau of RFET values near 1, falling abruptly to
a floor of near 0 values.
Next the BLANKET method will be used to evaluate data
from a classic microRNA (miRNA) microarray paper by
He et al. [14]. The spreadsheet data from the paper are in
the NCBI/NLM/GEO web site with Accession number
BLANKET applied to comparison of two illustrative lists of  500 descriptors Figure 1
BLANKET applied to comparison of two illustrative 
lists of 500 descriptors. The first ten from Experiment A 
appear in scrambled order within the first ten of Experiment 
B. BLANKET suggests that four combinations of shortlists 
are sufficiently coincidental to meet a p-value of .05. Note 
that three of the four selected shortlist pairs (p, q) have une-
qual numbers of selected descriptors.
Experiment A 
best shortlist pairs (9,2), (7,3), (4,4), (2,6) 
RFET Score
Experiment B BMC Bioinformatics 2009, 10:431 http://www.biomedcentral.com/1471-2105/10/431
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GSE2399, entitled "MicroRNA expression in lymphoma
lines" [9]. Two experiments evaluated miRNA expression
levels in cell lines OCI-Ly4 and OCI-Ly7 (both relative to
the same control cells); these cell lines carry amplification
of genomic region of interest 13q31-q32 that is thought to
be oncogenic. In each experiment the results from the cell
lines were compared to the same measurements of nor-
mal B-cells.
He et al. measured in quadruplicate for cases and for con-
trols 190 mature miRNA levels for normal B-cells and sev-
eral cell lines including OCI-Ly4 and OCI-Ly7. Thus
Experiment A includes the 190-by-8 output matrix of Nor-
mal (control) B-cell miRNA values versus OCI-Ly4 (case)
miRNA values, and as Experiment B the same from OCI-
Ly7 values. This yields p-values and hence rankings of the
two lists of 190 miRNAs.
We tested the hypothesis that the same miRNAs can differ-
entiate control B-cells from both of the two cases OCI-Ly4
and OCI-Ly7 by attempting to find informative subsets of
the 190 probes.
The BLANKET for these data is shown as the surface in Fig-
ure 3. This BLANKET finds that three combinations of
shortlists that achieve the p, q ≤ 10 threshold for n = 200,
namely, 1.50E-03 (Table 1). That is, RFET = 1.17E-03 for
(7,2); RFET = 7.02E-05 for (6,4); and RFET = 2.91E-04 for
(4,9). The top 7 of the OCI-Ly4 list are: let-7e, -7g, -7c, -7f,
-7d, -7a, and miR-373*. The top 9 of the OCI-Ly7 list are
miR-373*, let-7a, -7c, -7f, miR-138, -423, -15a, -223, and
let-7g.
It is already obvious from the heatmap in Figure 1 of the
He paper that the let-7 family is distinguished by case ver-
sus control. Aside from the let-7 family, the union of the
BLANKET shortlists contains five other miRNAs: hsa-miR-
373*, -138, -423, -15a, and -223. There is an interesting
alignment among these:
hsa-miR-138 5' AGCU-GGUGUUGUGAAUCAGGCCG 3'
           |||| |||
hsa-miR-423 5' AGCUCGGUCUGAGGCCCCUCAGU 3'
This alignment invites investigation because the bases
near the 5' terminus (the "seed region") are generally
thought by miRNA researchers to be most important in
terms of targeting and gene regulation [15]. Possibly the
similarity of miR-138 and miR-423 in this respect implies
the two are actually redundant; redundancy is considered
a hallmark of miRNA targeting efficacy [16]. Redundancy
BLANKET applied to a second set illustrative lists of n = 500  descriptors Figure 2
BLANKET applied to a second set illustrative lists of 
n = 500 descriptors. Descriptors in Experiment A are 
ranked in canonical order 1, 2, ..., 500. To the same ranking, 
weighted noise is added to arrive at an Experiment B ranking 
of 7, 26, 17, 32, 21, 34, 12, 46, 49, 14, 57, 54, 67, 19, 61, 28, 
1, 15, 82,... BLANKET finds no shortlists of length at most 10 
that meet the criteria for significance (p-value ≤ .05, corre-
sponding to RFET < .00105). However, BLANKET finds 
three shortlist pairs as shown of length < 20 that do meet 
the same (RFET < .00800). Thus BLANKET, not knowing the 
effects of noise, would recommend to the researcher these 
descriptors for further investigation. Note the characteristic 
sharp decline in RFET values near the chosen shortlists. This 
example is relevant to the case of one experiment performed 
with great accuracy and the other with substantial noise. 
Note that each selected shortlist pair (p, q) has unequal num-
bers of descriptors selected from both experiments (p ≠ q).
best shortlist pairs (17,3), (14,11), (12,18) 
Experiment A  Experiment B 
RFET Score 
BLANKET applied to ranked list date of 190 descriptors  from He et al. (He et al. 2005) Figure 3
BLANKET applied to ranked list date of 190 descrip-
tors from He et al. (He et al. 2005). BLANKET suggests 
that three combinations of shortlists are sufficiently coinci-
dental to meet a p-value of .05. Note that each selected 
shortlist pair (p, q) has unequal numbers of descriptors 
selected from both experiments (p ≠ q).
best shortlist pairs (7, 2), (6,4), (4, 9) 
OCI-Ly4 Exp.  OCI-Ly7 Exp. 
RFET Score BMC Bioinformatics 2009, 10:431 http://www.biomedcentral.com/1471-2105/10/431
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might allow fine tuning when one is upregulated in case
and the other downregulated, as is so for these miRNAs.
Otherwise, shortlisted descriptors might exhibit consist-
ent change associations between the two experiments, as
is the case for 7 of the other 9 miRNAs in the BLANKET
union of shortlists for these data.
BLANKET is next applied to suggest shortlists of genes
from experiments with lung adenocarcinoma measure-
ments versus control tissue measurements in microarray
studies by Stearman et al. and Bhattacharjee et al. [17,18].
Each study contains a statistical contrast of normal lung
tissue versus adenocarcinoma tissue. The gene symbols
and associated p-values from each study can be down-
loaded from Oncomine. The Stearman study considers
7815 genes (excluding ESTs and multiple measurements
for one gene); the number for Bhattacharjee is 7160.
Ranked by lowest p-values, the top 1000 genes in each
experiment can be selected. The intersection of the lists
can be reranked to a list of 289 genes that are possibly
informative in both experiments. BLANKET yields the sur-
face in Figure 4.
From the Stearman data BLANKET chooses 14 genes:
GPC3, SOX4, GRK5, ADH1B, CLEC3B, MFAP4, TEK, FH1,
AOC3, TBX2, COX7A1, TGFBR3, MYLK, VWF. BLANKET
chooses 8 genes from the Bhattacharjee data: HYAL2,
GRK5, SPOCK2, ENO1, SEMA5A, CDH5, VWF, COX7A1.
Thus the intersection is {GRK5, COX7A1, VWF} with
RFET = 4.42E-03.
Interestingly, several additional papers connect some of
the shortlisted genes with lung cancer. Regarding GPC3,
Powell et al. used microarrays to identify GPC3 as one of
several genes the expression of which was lower in the
healthy lung tissue of smokers than in nonsmokers and
was lower in tumor tissue than in healthy tissue [19].
Additionally, northern blot analysis demonstrated that
GPC3 expression was absent in 9 of 10 lung cancer cell
lines. Regarding ADH1B, Kopantzev et al. employed
cDNAs sequencing and RT-qPCR analysis to measure
genes differentiated in comparison of human fetal versus
adult lungs and in normal lung tissue versus non-small
lung cell carcinomas [20]. ADH1B was one of 12 genes
found to have opposite differentiation in the two compar-
isons. Regarding CLEC3B, reduced plasma levels have
long been associated with cancer and metastasis [21].
Regarding TEK, Millauer et al. implicated TEK among
growth factor receptor tyrosine kinases in angiogenesis,
and Findley et al. demonstrated that VEGF regulates TEK
signaling [22,23]. Regarding AOC3, Singh et al. found
that expression may contribute to the functional heteroge-
neity of endothelial cells within the lung to create distinct
sites for the recruitment of inflammatory cells [24].
Regarding HYAL2, Li et al. studied genetic aberrations in
the genes HYAL2, FHIT, and other genes in paired tumors
and sputum samples from 38 patients with stage I non-
small cell lung cancer and in sputum samples from 36
cancer-free smokers and 28 healthy nonsmokers [25].
They found HYAL2 and FHIT were deleted in 84% and
79% tumors and in 45% and 40% paired sputum sam-
ples. Regarding ENO1, Chang et al. observed that only a
limited number of immunogenic tumor-associated anti-
gens have been identified and associated with lung cancer
[26]. They reported up-regulation of ENO1 expression in
effusion tumor cells from 11 of 17 patients compared
with human normal lung primary epithelial and non-can-
cer-associated effusion cells. Regarding MYLK, Soung et al.
analyzed exons 6 and 7 encoding the kinase domain for
somatic mutations in 60 gastric, 104 colorectal, 79 non-
small cell lung, and 54 breast cancers [27]. They found
one MYLK2 mutation in lung adenocarcinomas, but not
in other cancers. Regarding SEMA5A, Sadanandam et al.
demonstrated an association between the expression of
SEMA5A and Plexin B3 and the aggressiveness of pancre-
Table 1: BLANKET multiple comparison-corrected significance 
threshold values for p-value 0.05.
np ,  q  ≤ 20 p, q ≤ 10
100 0.00424 0.00192
200 0.00549 0.00150
300 0.00666 0.00119
400 0.00657 0.00104
500 0.00800 0.00105
BLANKET applied to comparison of 289 genes within lung  cancer microarray studies of Stearman and Bhattacharjee Figure 4
BLANKET applied to comparison of 289 genes within 
lung cancer microarray studies of Stearman and 
Bhattacharjee. One pair of shortlists with 14 descriptors 
from the first and eight from the second yields a RFET score 
= .0044; this is less than .0066, the level that insures a p-value 
significance level (.05) for any shortlists with twenty or fewer 
members from a universe of 300 members.
Stearman  
Experiment 
Bhattacharjee Experiment
best shortlist pair (14,8)  RFET ScoreBMC Bioinformatics 2009, 10:431 http://www.biomedcentral.com/1471-2105/10/431
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atic and prostate cancer cells [28]. They deduced that
SEMA5A is among functional tumor-specific CAM genes,
which may be critical for organ-specific metastasis.
Regarding CDH5 and intersection gene VWF, Smirnov et
al. reported increased numbers of endothelial cells in
peripheral blood of cancer patients [29]. They found
expression of VWF, DTR, CDH5, TIE, and IGFBP7 genes
discriminated between cancer patients and healthy
donors with a receiver operating characteristic curve accu-
racy of 0.93. Of the other two genes in the intersection,
GRK5 is a G protein-coupled receptor kinase and is highly
expressed in lung [30]. Lastly, COX7A1 is 13 kb from and
possibly co-expressed with FXYD5 (alias dysadherin), a
cancer-associated cell membrane glycoprotein that pro-
motes experimental cancer metastasis [31].
In summary, there are potential lung cancer connections
with genes in the Stearman-Bhattacharjee BLANKET
shortlists. This illustrates the main output of BLANKET,
namely, suggestions to researchers of small subsets of
genes especially worthy of further investigation.
The next analysis pertains to an instance in which BLAN-
KET does not suggest informative shortlists; this example
compares results of Stearman with another lung cancer
study by Beer et al. [32]. Preprocessing starting with the
1000 most differentiated gene lists leads to selection of
489 shared genes. As shown in Figure 5, the BLANKET sur-
face does not display a sharply defined subset of informa-
tive descriptors, that is, no plateau that falls precipitously
to a floor of RFET values near zero.
Lastly, BLANKET applied to the third possible combina-
tion of tests (Beer-Bhattacharjee) is not interesting. It finds
a very small subset pair (2,5). Such small shortlists are evi-
dent by inspection because the top two for Beer are
ADH1B and CLEC3B while the top five for Bhattacharjee
are GPC3, SOX4, GRK5, ADH1B, CLEC3B.
Implementation
Following is a pipeline (for R code see Additional File 1)
for processing descriptors measured in two experiments
called A and B. Each experiment routinely yields a matrix
of values with descriptors labeling the rows and samples
labeling the columns. An additional column is the
informativeness of each descriptor from application of
Student t-testing or another method; that additional col-
umn is used to rank the descriptors by informativeness,
yielding the two ranked descriptor lists used as inputs by
BLANKET.
Considerable preprocessing might be needed to derive the
ranked lists. This is because the raw data (e.g. mRNA
microarrays) typically have many thousands of descrip-
tors, from which one distills hundreds that are signifi-
cantly up or down in case versus control; the researcher
might wish to treat up- and downregulated genes sepa-
rately. The intersection of the two lists must be found and
then a selection made of the topmost descriptors (such as
the top 500) of the two lists. Some of the top 500 in one
list might not be in the top 500 of the other, so a second
intersection is needed to yield a list of genes with different
rankings in the two experiments, that is, somewhat fewer,
shared, ranked descriptors suitable for BLANKET. Real
data tested in preparation of this paper yielded an inter-
section n = ~250 to ~450 descriptors.
Using the list of shared descriptors and selecting the top p
descriptors from A and the top q descriptors from B yields
a contingency table. Over the discrete plane of all possible
pairs, RFET values can be represented as a blanket-like sur-
face.
Table 1 shows for various n values and two reasonable
upper limits on p and q the low RFET values that are
attained by only 5% of random lists. For n = 100, 200, and
300, the entries are based on 500 simulations. For n = 400
and 500, they are based on 1000 simulations. Thus, for
example, a researcher who distills experimental informa-
tion down to two ranked lists of 200 descriptors and finds
a shortlist pair (p, q) with p and q ≤ 20 and RFET = .004
(< .00549) can dismiss the null hypothesis with a 5% false
positive rate.
After finding shortlist pairs that provide RFET values lower
than the values in Table 1, the researcher should select
shortlists as follows: For each selected shortlist pair (p, q),
no other shortlist pair (p', q') also has p' ≤ p, q' ≤ q, and
p'+q' < p+q.
BLANKET applied to comparison of lung cancer microarray  studies of Beer and Stearman Figure 5
BLANKET applied to comparison of lung cancer 
microarray studies of Beer and Stearman. The method 
fails to find a threshold pair with low RFET score < .00800, 
which would be sufficient for shortlists with up to 20 mem-
bers to have statistical significance in a universe of 489 
descriptors. This surface is more organized than random 
BLANKETs, since there is a sharp decrease from 1 to low 
values, but it is less organized than those in Figures 3 and 4.
Beer Experiment  Stearman Experiment 
RFET Score BMC Bioinformatics 2009, 10:431 http://www.biomedcentral.com/1471-2105/10/431
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All such values and corresponding descriptors should be
noted by the researcher. All genes that achieve a level of
informativeness discovered in a BLANKET selection might
be considered. That is, the union of all the descriptors in
the shortlists might be informative, as well as, of course,
the intersection. If several pairs of shortlists fulfill this
condition, then minimizing the RFET values or minimiz-
ing p+q might yield especially interesting shortlist pairs.
Results
If two experiments of case versus control have substan-
tially overlapping descriptor sets and a consistent, binary
categorization of outcome, then standard statistical anal-
yses can provide two lists, ranked by informativeness, of
the shared descriptors. The ranked lists suggest two ques-
tions:
Question 1: From the results of the two experiments, is
there a minimal subset of descriptors that predicts experi-
mental outcome much better than smaller subsets and
about as well as any larger subsets?
Question 2: If existence of such a minimal subset is indi-
cated, then what are its members?
The focus here is on one method that answers these ques-
tions. We call our method BLANKET; this is not an acro-
nym, but merely a term suggestive of a blanket-like surface
suspended above a plane of shortlist length pairs.
Suppose two experiments such as microarray analyses
investigate informativeness of descriptors relative to a
property of samples. Here a descriptor (predictor) is any
tested type of measurement, such as detection of messen-
ger RNA of a certain gene in a microarray experiment (a
continuous variable) or presence or absence of a certain
chemical substructure in a compound evaluated for toxic-
ity (a binary variable). A property of the samples could be
case versus control, survival time, or another characteristic
or outcome of interest. BLANKET treats the set of shared
descriptors as two ranked lists.
The informativeness of each descriptor, considered in iso-
lation, can be determined by a by t-test, z-test, or other
method; our only requirement is that informativeness
analysis for each experiment yields a ranked list. The two
experiments might use the same or different definitions of
informativeness.
The basic idea of BLANKET is consideration of shortlists
of descriptors from each experiment, say the top p of n
descriptors of Experiment A and the top q of the same n
descriptors of Experiment B. For any such pair of short-
lists, four numbers are evident: the number of descriptors
appearing in both shortlists, in exactly one shortlist, or in
neither shortlist. The sum of all four is n; the sum of the
first two is p; and the sum of the first and third is q. BLAN-
KET computes Right Fisher Exact Test (RFET) values used
as scores over a discrete plane of all possible pairs of short-
list lengths (so all (p, q) with 0 ≤ p, q ≤ n). BLANKET then
chooses one pair or a few pairs with RFET score less than
a threshold; the threshold depends upon n and upper
bounds of shortlist lengths. The threshold has been deter-
mined by simulations and represents a quality of RFET
value achieved by only 5% of random lists. A further prop-
erty of a pair (p, q) selected by BLANKET is parsimony,
that is, that no other pair (p', q') exists with p' ≤ p, q' ≤ q,
p'+q' < p+q, and an RFET score that also survives the
threshold. Multiple shortlists could be scored by small-
ness of p+q.
Furthermore, we seek to represent the information to the
researcher in a visual form such as an Excel spreadsheet
surface graph that invites assessment based upon a
researcher's experience with data of a given type, much in
the manner of the commonplace heatmap.
Theoretical basis
Our approach is to consider the RFET value for all combi-
nations of shortlist lengths 10 or 20 within ranked
descriptor lists of length n = 100, 200, 300, 400, or 500.
In the grid of lengths, this can be thought of as the exam-
ination of all p-by-q rectangles of RFET values within a
given nxn square, subject to p ≤ n and q ≤ n. The RFET
attaining the minimum nominal p-value is then com-
pared to the null distribution of such minimum p-values,
obtained via permutation, which assumes that the order-
ings of the two lists of descriptors are random. The corre-
sponding 0.05 quantile values are used as rejection
thresholds for controlling the overall Type I error at 0.05.
Formally, the approach is the single-step Westfall-Young
permutation p-value for potentially correlated tests,
which controls the family-wise error and avoids the exces-
sive conservativeness of Bonferroni bounds [33]. Further-
more, the approach has an exact interpretation as a kind
of randomization test of a statistic (minimum nominal p-
value) in a population of equally likely outcomes (align-
ment of descriptor lists) conditioned on some aspect of
the data (descriptor identities) [34]. This is an attractive
approach, as it makes very few assumptions about the
data and is entirely nonparametric.
Discussion
The term BLANKET reflects the shapes of the surfaces in
Figures 1, 2, 3, 4 and 5. We can reason as follows about the
shape. If the threshold for at least one of the lists is too
strict (very small or zero) so that one shortlist is empty or
small and there is no intersection, then RFET = 1; likewise,
if at least one shortlist is the universe of descriptors, thenBMC Bioinformatics 2009, 10:431 http://www.biomedcentral.com/1471-2105/10/431
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RFET = 1. Thus the boundary of the BLANKET surface over
the full range of all threshold pairs necessarily has fixed
value 1. This insures that seeking interior points with rel-
atively low RFET values on the surface makes sense.
To our knowledge, BLANKET is a novel means for nomi-
nating distinguished subsets of descriptors from data from
two experiments. BLANKET suggests shortlists (subsets) of
genes from each list, where the shortlists achieve a certain
level of informativeness individually. The subsets then
collectively differentiate case from control. While the pre-
processing considers the full ranked lists, BLANKET does
not make global declarations. That is, BLANKET ignores
very uninformative descriptors but can tolerate descrip-
tors with marginal p-values provided they consistently
appear among the best found of ranked lists.
Other related scores that might be substituted for the RFET
score are Pearson's chi-square test and the G-test [35,36].
Once a distinguished set of descriptors has been verified,
dependencies among the descriptors might be discovered
by applying Cronbach's α test [37].
Another meta-analysis paper is that of Blangiardo and
Richardson [38]. They also scored 2-by-2 contingency
tables derived from ranked lists, seeking a "...parsimoni-
ous list associated with the strongest evidence of depend-
ence between experiments." Their pioneering work differs
from ours three respects.
First is their use of a given number (101) of bins so that a
bin could contain all of a subset of descriptors with close
p-values. Second, the hypergeometric distribution is the
score of the paired bins as shortlists. (By definition, hyper-
geometric distribution is the chance probability of exactly
a given intersection size of subsets of p and q elements
from a universe of n elements; RFET is the probability of
that number of intersection elements or more, limited by
max {min {p, q}}. Thus RFET is a decreasing sum of a
finite number of hypergeometric terms, the first of which
was the score used by Blangiardo and Richardson.)
Third, and perhaps most importantly, they only scored
shortlists of equal length, hence the diagonal of the dis-
crete space of all combinations of bin sizes. By contrast we
consider all "rectangular" combinations of shortlists
lengths that lie within a larger "square" (such as 20-by-20)
of combinations.
The significance of the restriction of consideration to
shortlists of equal length can be illustrated as follows.
Suppose that two experiments test 100 descriptors for case
and control informativeness, providing two ranked lists.
Suppose the first experiment is very accurate but the sec-
ond is not; perhaps the second employs a noisier technol-
ogy but still might provide a degree of confirmation.
Suppose the top four descriptors in the first experiment
appear in rank positions 5, 10, 15, 20 of the second, and
that no other descriptors in the top twenties are shared.
BLANKET correctly selects the top 4 of the first list and the
top 20 of the second, with RFET = .00124 < .00424 in
Table 1. However, requiring shortlists of equal length
forces consideration of the top 5, 10, 15, and 20 of both
lists. This results in RFET and hypergeometric distribution
p-values all above .2. That is, restricting consideration to
shortlists of equal length would find no informative
shortlists and in particular would miss the combination
(4, 20) found by BLANKET.
Regarding other related papers, we note that Hess and Iyer
reported that Fisher's combined p method applied to
microarray data from spike-in experiments with RT-qPCR
validation usually compared favorably to other methods
[4]. As they further noted, current methods for analyzing
microarray data do better at ranking genes rather than
maintaining stated false positive rates.
Breitling et al., devised the "rank product" method which
in simplest form uses multiplication across N experiments
of the reciprocal of rank positions of N descriptors, lead-
ing to a kind of global ranking [39,40]. In some cases, two
logically distinct lines of experimentation might lead to
two classes, each including many experiments. The rank
product approach might be applied to experiments from
one class and then the other, and the two resulting global
ranked lists be submitted to BLANKET. For example, in
the context of a given case versus control study, a global
ranked list could be derived from many microarray exper-
iments. Then the same genes could be ranked from key-
word studies of research papers associating them with case
outcomes, again producing a global ranked list. Finally,
the two global ranked lists, from very different lines of
investigation, could be analyzed by BLANKET to discover
collectively informative subsets of genes.
An enhancement of BLANKET in gene expression analysis
of microarrays might include consistency of fold change.
That is, the researcher might require that the genes in the
intersection of shortlists all have fold change > 1 or all
have fold change < 1 for case versus control. Doing this for
randomly generated ranked lists and random fold changes
would result in a table like Table 1 but with increased val-
ues.
Conclusions
The BLANKET method provides a visual representation of
optimal selections of subsets of informative descriptors. A
key observation in our real data is that there can be an
abruptly lower (better) RFET score value, going from a
plateau of almost 1 to a valley floor of almost 0 values asBMC Bioinformatics 2009, 10:431 http://www.biomedcentral.com/1471-2105/10/431
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shortlist lengths are slightly incremented. Furthermore, if
upper limits on the shortlist lengths are specified as 10 or
20, then our simulations provide values for RFET scores
that allow rejection of the null hypothesis with 95% cer-
tainty. In such circumstances, BLANKET can suggest a
sharp distinction between slightly too few and slightly too
many descriptors, that is, a classifier based upon optimal
collective informativeness.
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